Gliflozine e sindrome cardio-renale

SGLT2 inhibitors are molecules able to reduce blood glucose levels and body weight, lower systolic pressure. They also exert important diuretic modulatory effects of renal hemodynamics, as well a series anti-inflammatory actions, thus contributing the cardiovascular burden in subjects with without type 2 diabetes. Such benefit mainly translates into reduced risk for hospitalization due heart failure, decline glomerular filtration, associated powerful anti-albuminuric effect. For this reason, they constitute an indispensable treatment modern approach cardiorenal prevention. This review recapitulates clinical evidence supporting use these patients, main mechanisms protection.